Our team at VIC recently published an opinion article published in Trends in Immunology Journal under the guidance of Dr. Gemechu. Immunotherapies have revolutionized treatment outcomes for cancer, but many cancers are resistant to such therapies. Cancers have an altered environment compared to healthy tissue, and part of this is due to changes in the metabolism of cancer cells. Recent research has centered on modifying such metabolic pathways combined with cancer immunotherapies. In this opinion piece, we explored the potential pitfalls of current preclinical research and how these can be addressed to accelerate the development of such drugs. We also analyzed the results of published clinical trials and suggested improvements for the methodology of preclinical studies. We hope that in the future, researchers can consider these ideas in their preclinical research, resulting in successful outcomes in clinical trials.

Recommended Posts